Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...
Copaxone (glatiramer acetate injection) has potential interactions with other medications. These interactions could cause harmful effects. Copaxone is used in adults to treat relapsing forms of ...
The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results